

**JOINT PROMOTION AGREEMENT ON ANTIEMETIC AGENT
WITH HELSINN THERAPEUTICS INC. IN THE UNITED STATES REVISED**

*Eisai to Return All Rights to Promote and Distribute
AKYNZEO[®] (netupitant/palonosetron) to Helsinn Therapeutics Inc.*

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has agreed to revise the joint promotion agreement with Helsinn Healthcare S.A. (Headquarters: Lugano, Switzerland, Group Vice Chairman and CEO: Riccardo Braglia, "Helsinn") for their chemotherapy-induced nausea and vomiting (CINV) franchise.

[Notes to editors]

1. About AKYNZEO®

AKYNZEO is a new oral fixed combination that targets two critical signaling pathways associated with CINIV, by combining netupitant, an NK₁ receptor antagonist, with palonosetron, a 5-HT₃ receptor antagonist. Marketing authorization applications for AKYNZEO are currently being submitted in countries throughout the world.

2. About the Helsinn Group

Helsinn is a privately owned cancer supportive care pharmaceutical group with an extensive portfolio of marketed